Science writer and independent researcher specialising in natural compound pharmacology and translational oncology. Tracking EBC-46 (tigilanol tiglate) and Blushwood berry extract since 2019.
EBC-46
EBC-46 works by mimicking diacylglycerol to activate PKC-delta, triggering a cascade of vascular disruption and immune recruitment that destroys tumours from within.
EBC-46
Stelfonta became the first tigilanol tiglate product approved by the FDA. Understanding its regulatory journey maps the path EBC-46 must follow for human approval.
EBC-46
Intratumoral EBC-46 is designed to stay local — but how much reaches systemic circulation, and what does the body do with it? A detailed look at tigilanol tiglate pharmacokinetics.
EBC-46
EBC-46 has received Orphan Drug Designation from the FDA for specific rare cancers. Here's what that regulatory milestone actually means — and why it matters for patients.
EBC-46
When a local injection shrinks tumours far from the injection site, something remarkable is happening. Here's what research reveals about EBC-46 and systemic anti-tumour immunity.
stelfonta
How EBC-46 became Stelfonta® — the first FDA and EMA approved intratumoral cancer treatment — through rigorous canine clinical trials, and what this milestone means for the ongoing Phase I/II human cancer trials.
Clinical Trials
A detailed review of EBC-46 (tigilanol tiglate) human clinical trial data through 2025–2026, including Phase I/II results for soft tissue sarcoma, melanoma, and other solid tumours, response rates, and the path to FDA approval.
EBC-46
A deep-dive into how tigilanol tiglate (EBC-46) destroys tumours through three distinct pathways: PKC activation, rapid vascular disruption, and immune-mediated clearance — with full citations to the primary research.
Blushwood Berry
Everything known about the Blushwood tree (Fontainea picrosperma) as the natural source of EBC-46, the science behind the extract, and what supplement users are reporting — including energy, immune support, inflammation, and skin benefits.
EBC-46
The definitive reference on EBC-46 (tigilanol tiglate): its chemistry, mechanism of action, veterinary approval as Stelfonta®, ongoing human Phase I/II trials, Blushwood berry source, and what current science says for patients and supplement users.